Original PDF Flash format curriculum-vitae  


Curriculum Vitae

JEFFREY S.MORRIS
January 2010
CURRICULUM VITAE

Name:
Jeffrey S. Morris, Ph.D.
Address:
Department of Biostatistics


The University of Texas M.D. Anderson Cancer Center
P.O.
Box
301402
Houston,
TX
77230-1402


(713) 563-4284 (Office);
(979) 563-4243 (Fax)


jefmorris@mdanderson.org


http://biostatistics.mdanderson.org/Morris


http://works.bepress.com/jeffrey_s_morris/

DATE OF BIRTH December 6, 1970
EDUCATION
Ph.D., Statistics, Texas A&M University, August 2000.
Advisors: Raymond J. Carroll and Naisyin Wang


M.S., Statistics, Texas A&M University, December 1997.


B.S., Mathematics Education, Messiah College, May 1993.

PROFESSIONAL EXPERIENCE

September 2010- : Professor, Department of Biostatistics, The University of Texas
MD Anderson Cancer Center
September 2005-August 2010: Associate Professor, Department of Biostatistics, The
University of Texas MD Anderson Cancer Center.
May 2001-July 2001: Visiting Fellow, The University of Kent at Canterbury.

August 2000-August 2005: Assistant Professor, Department of Biostatistics, The
University of Texas MD Anderson Cancer Center.


June 1998-August 2000: Research Assistant, Texas A&M University.


January 1998-May 1998: Assistant Lecturer, Texas A&M University.


May 1997-July 1997: Intern, Hoechst Marion Roussel, Kansas City, MO.
August 1995-December 1997: Teaching Assistant, Texas A&M University


August 1993-August 1995: Teacher, Northside Christian School, St. Petersburg, FL


January 1993-July 1993: Programmer, IBM, Mechanicsburg, PA.
HONORS
H. O. Hartley Award, Texas A&M University Department of Statistics, 2009
American Statistical Association Noether Young Scholar Award, 2005
Thomson-ESI Hot Paper in the Field of Computer Science, July 2005

1

JEFFREY S.MORRIS
MD Anderson Cancer Center E.N. Cobb Faculty Scholar Award, 2004
Best Presentation, 4th Critical Assessment of Microarray Data Analysis, 2003
Mitchell Prize for Outstanding Bayesian Application Paper, 2003
JASA Applications and Case Studies Editor’s Invited Paper, 2003
Best Abstract, 1st Annual Proteomics Data Mining Conference, 2002
Travel Award for Young Researchers, Biometrics Section of ASA, 2001
Texas A&M College of Science Dean’s Graduate Fellowship, 1995
Texas A&M University Graduate Merit Fellowship, 1995

RESEARCH GRANTS AND CONTRACTS

Current:
National Cancer Institute (CA-107304), R01, Adaptive Methods for Biomedical
Functional Data, 2004-present (PI). Funded through 2012.
National Cancer Institute (CA-016672), P30, Cancer Center Support Grant, 2000-
present (Statistician, John Mendelsohn PI). Funded through 2013.
National Cancer Institute (CA-098380), R01, Molecular Epidemiology of Pancreatic
Cancer, 2004-present (Statistician, Donghui Li PI). Funded through 2009.
National Cancer Institute (CA-106577), R01, 5-LOX-1 and Clinical
Chemoprevention of Colon Tumors, 2005-present (Collaborator, Imad Shureiqi
PI). Funded through 2009.
National Institute for Alcohol Abuse (AA-016157), R01, Brain Biomarkers of
Alcoholism and Abstinence, 2006-present (co-PI, Howard Gutstein PI). Funded
through 2011.
National Cancer Institute (CA-139767), R13, Conference on “Statistical Methods for
Complex Biological Data”, Funded through 2010 (PI).
National Cancer Institute, K23, SrC Inhibition in Colorectal Cancer, Funded through
2012. (Statistician, Scott Kopetz PI).
National Cancer Institute, R01, Molecular Targeting of PPAR-delta in colon cancer,
(Statistician, Imad Shureiqi, PI), Funded through 2011.


Completed:
National Institute on Drug Abuse (DA-0154604), R01, From Drug Use to Addiction:
Unearthing the Switches, 2002-2007 (Collaborator, Howard Gutstein PI).
National Institute for Alcohol Abuse (AA-1388602), R56, Proteomic Approaches to
Alcoholism, 2005-2008 (Collaborator, Howard Gutstein PI).
National Cancer Institute (CN-005126), N01, A Phase I/II Study of Celecoxib in
Genotype-Positive, Phenotype-Negative Children with FAR, 2000-2007
(Statistician, Patrick Lynch PI).


American Cancer Society (RSG-04-020-01-CNE), 15-Lipoxygenase-1 and
Mechanisms of Colorectal Tumorigenesis, 2004-2007 (Statistician, Imad
Shureiqi PI).
National Cancer Institute (CA-104278), R01, Molecular Targeting of 15-
Lipoxygenase-1 Colon Cancer, 2004-2008 (Statistician, Imad Shureiqi PI).

2

JEFFREY S.MORRIS

Submitted/Pending:


National Institute on Drug Abuse (DA-027498), R21/R33, Secondary Analyses in
Addiction using Novel Methods for Complex Functional Data (Principal
Investigator), Requested period of support: 2009-2013.


National Institute of Health Roadmap Transformative R01 Program (OD-006329),
Biomarkers of the Transition from Acute to Chronic Pain, 2009-2014 (Principal
Investigator, MPI with Howard Gutstein, Jonathan Sweedler, and Mark
Bedford), Requested period of support: 2009-2014.
National Cancer Institute, R21, Validating Human Mid-gut Carcinoid Tumor Stem
Cells, (Statistician, Lee Ellis, PI), Requested period of support: 2009-2013.


National Cancer Institute, R01, Development of Validation of Multi-Modal, Multi-
Scale Optical Molecular Imaging for Early Detection of Neoplasia, (Statistician,
Sharmalia Ananda, PI), Requested period of support: 2009-2014.


National Cancer Institute, Challenge Grant, Inflammation in Pancreatic Cancer,
(Statistician, Donghui Li, PI), Requested period of support 2009-2011.
National Cancer Institute, Challenge Grant, Prospective Validation of Angiogenic
Predictive and Prognostic Markers in HCC, (Co-Investigator, Ahmed Kaseb PI),
Requested period of support: 2009-2011.
National Cancer Institute, Challenge Grant, Assessing the Impact of Single Nucleotide
Polymorphisms (SNPs) on Pancreatic Cancer (PC) Symptomology, (Statistician,
David Fogelman PI), Requested period of support: 2009-2011.
National Cancer Institute, R21, Early Detection of Pancreatic Cancer in High-Risk
Individuals, (Co-Investigator, Jianjun Shen), Requested period of support: 2009-
2011.


Patents:
Pinnacle-based method using average gels for improved spot detection and
quantification of 2D gels, US Patent Application 2080166030.



PUBLICATIONS

[1] Hong MY, Chapkin RS, Wild CP, Morris JS, Wang N, Carroll RJ, Turner ND and Lupton JR
(1999). Relationship Between DNA Adduct Levels, Repair Enzyme and Apoptosis as a
Function of DNA Alkylation by Azoxymethane. Cell Growth and Differentiation, 10: 749-758.
[2] Hong MY, Lupton JR, Morris JS, Wang N, Carroll RJ, Davidson LA, Elder R and Chapkin RS
(2000). Dietary Fish Oil Reduces 06-methylguanine DNA Adduct Levels in the Rat Colon In
Part By Increasing Apoptosis During Tumor Initiation. Cancer Epidemiology, Biomarkers and
Prevention, 9: 819-826.
[3] Davidson LA, Brown RE, Chang W-CL, Lupton JR, Morris JS, Wang N, Carroll, RJ, Turner,
ND and Chapkin, RS (2000). Morphodensitometric Analysis of Protein Kinase C II Expression
in the Rat Colon: Modulation by Diet and Relation to in situ Cell Proliferation and Apoptosis.
Carcinogenesis, 21: 1513-1519.
[4] Rashid A, Lanlan S, Morris JS, Issa J-PJ, Hamilton SR (2001). CpG island methylation in
colorectal adenomas. The American Journal of Pathology, 159:1129-1135.

3

JEFFREY S.MORRIS
[5] Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY and Carroll RJ (2001).
Parametric and Nonparametric Methods for Understanding the Relationship Between
Carcinogen-Induced DNA Adduct Levels in Distal and Proximal Regions of the Colon. Journal
of the American Statistical Association, 96: 816-826.
[6] Shureiqi I, Cook CD, Morris JS, Soliman AS, Levin B, and Lippman SM (2001). Effect of Age
on Risk of Second Primary Colorectal Cancer. Journal of the National Cancer Institute, 93:
1264-1265.
[7] Hong MY, Chapkin RS, Morris JS, Wang N, Carroll RJ, Turner ND, Chang WCL, Davidson
FA and Lupton JR (2001). Anatomical Site-Specific Response to DNA Damage is Related to
Later Tumor Development in the Rat AOM Colon Carcinogenesis Model. Carcinogenesis,
22:1831-1835.
[8] Arrington JL, Chapkin RS, Switzer KC, Morris JS and McMurray DN (2001). Dietary n-3
Polyunsaturated Fatty Acids Modulate Purified Murine T-cell Subset Activation. Clinical and
Experimental Immunology, 125: 499-507.
[9] Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM and Lippman SM (2001).
Nonsteroidal Anti-inflammatory Drugs Induce Apoptosis in Esophageal Cancer Cells by
Restoring 15-Lipoxygenase-1 Expression. Cancer Research 61: 4879-4884.
[10] Chan AOO, Issa-J-PJ, Morris JS, Hamilton SR and Rashid A: Concordant CpG Island
Methylation in Hyperplastic Polyposis (2002). The American Journal of Pathology, 160: 529-
536.
[11] Morris JS (2002). The BLUPs Are Not “Best” When It Comes To Bootstrapping. Statistics
and Probability Letters, 56: 425-430.
[12] Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY and Carroll RJ (2002). A
Bayesian Analysis Involving Colonic Crypt Structure and Coordinated Response to Carcinogens
Incorporating Missing Crypts, Biostatistics, 3: 529-546.
[13] Baggerly K, Deng L, Morris JS, Aldez CM (2003). Differential expression in SAGE:
Accounting for normal between-library variation. Bioinformatics, 19(12): 1477-1483.
[14] Baggerly K, Morris JS, Wang J, Gold D, Xiao LC and Coombes K (2003). A comprehensive
approach to the analysis of MALDI-TOF proteomics spectra from serum samples. Proteomics,
3: 1667-1672 (Won Best Presentation at 2002 Duke University Proteomics Data Mining
Competition).
[15] Morris JS, Baggerly K, and Coombes K (2003). Bayesian Shrinkage Estimators of the Relative
Abundance of mRNA Transcripts using SAGE. Biometrics, 59: 476-486.
[16] Morris JS, Vannucci M, Brown PJ and Carroll RJ (2003). Wavelet-Based Nonparametric
Modeling of Hierarchical Functions in Colon Carcinogenesis [with discussion]. Journal of the
American Statistical Association, 98: 573-583 (Editor’s Invited Paper and chosen to receive
Mitchell Prize).
[17] Coombes KR, Fritsche HA Jr., Clarke C, Cheng JN, Baggerly KA, Morris JS, Xiao LC, Hung
MC, and Kuerer HM (2003). Quality Control and Peak Finding for Proteomics Data Collected
from Nipple Aspirate Fluid Using Surface Enhanced Laser Desorption and Ionization. Clinical
Chemistry, 49(10): 1615-1623.

4

JEFFREY S.MORRIS
[18] Morris JS, Wang N, Lupton JR, Chapkin RS, Turner ND, Hong MY, and Carroll RJ (2003).
Understanding the Relationship between Carcinogen-induced DNA Adduct Levels in Distal and
Proximal Regions of the Colon. Advances in Experimental Medicine and Biology, 537: 105-
116.
[19] Lin E, Morris JS, and Ayers GD (2003). Effect of Celecoxib on capecitabine-induced hand-
foot syndrome and antitumor activity. Oncology, 16 (12 supplement No 14): 31-37.
[20] Madoff DC, Hicks ME, Abdalla EK, Morris JS and Vauthey JN (2003). Portal vein
embolization using polyvinyl alcohol particles and coils in preparation for major liver resection
for hepatobiliary malignancy: Safety and Efficacy: A study in 26 patients. Radiology, 227(1):
251-260.
[21] Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer
SM, Lippman SM (2003). The 15-lipoxygenase-1 product 13-S-hydroxyocta-decadienoic acid
down-regulates PPAR-{delta} to induce apoptosis in colorectal cancer cells. Proceedings of the
National Academy of Sciences, 100(17): 9968-9973.
[22] Pawlik TM, Paulino AF, Mcginn CJ, Baker LH, Cohen DS, Morris JS, Rees R, and Sondak VK
(2003). Cutaneous angiosarcoma of the scalp: A multidisciplinary approach. Cancer, 98(8):
1716-1726.
[23] Pawlik TM, Izzo F, Cohen DS, Morris JS, and Curley SA (2003). Combined resection and
radiofrequency ablation for advanced hepatic malignancies: Results in 172 patients. Journal of
Surgical Oncology, 10(9): 1059-1069.
[24] Baggerly, KA, Morris JS, and Coombes KR (2004). Reproducibility of SELDI Mass
Spectrometry Patterns in Serum: Comparing Proteomic Data Sets from Different Experiments.
Bioinformatics, 20(5): 777-785 (Identified by Thomson-ISI as “one of the most cited recent
papers in the field of computer science”,see http://www.esi-topics.com/nhp/2005/july-05-
KeithBaggerly.html).
[25] Baggerly KA, Edmonson S, Morris JS, and Coombes KR (2004). High-Resolution Serum
Proteomic Patterns for Ovarian Cancer Detection. Endocrine-Related Cancers, 11(4): 583-584.
[26] Baggerly KA, Deng L, Morris JS, and Aldez CM (2004). Overdispersed Logistic Regression
for SAGE: Modeling Multiple Groups and Covariates. BMC Bioinformatics, 5:144.
[27] Marron JS, Muller HG, Rice J, Wang JL, Wang N, Wang Y, Coull B, Fahrmeier L, Guo W, Hall
P, Harezlak J, Huang J, Kneip A, Lin X, Morris JS, Pourmadi M, Staudenmayer J, Wu C,
Zhang D, Zhang H, and Zhao Y (2004). Discussion of nonparametric and semiparametric
regression. Statistica Sinica 14(3): 615-621.
[28] Sinicrope FA, Half E., Morris JS, Lynch PM, Morrow JD, Levin B, Steinbach G, Hawk ET,
Cohen DS, Ayers GD, Stephens LC, FAP Study Group (2004). Cell proliferation and apoptotic
indices predict adenoma regression in a placebo-controlled trial of celecoxib in Familial
Adenomatous Polyposis (FAP) patients. Cancer Epidemiology, Biomarkers, and Prevention,
13(6): 1-8.
[29] Ajani J, Walsch G, Komaki RR, Morris JS, Swisher SG, Lynch P, Wu TT, Vaporciyan A,
Faust JC, Nivers RJ, and Roth J (2004). Preoperative induction CPT-11 and cisplatin

5

JEFFREY S.MORRIS
chemotherapy followed by chemoradiotherapy in patients with local-regional carcinoma of the
esophagus or gastroesophageal junction. Cancer, 100(11): 2347-2354.
[30] Ajani JA, Mansfield PF, Janjan N, Morris JS, Pisters PW, Lynch PM, Feig B, Myerson R,
Nivers R, Cohen DS, and Gunderson LL (2004). A multi-institutional trial of preoperative
chemoradiotherapy in patients with potentially resectable gastric carcinoma. Journal of Clinical
Oncology, 22(14), 2774-2780.
[31] Baggerly KA, Morris JS, Edmonson S, and Coombes KR (2005). Signal in Noise: Evaluating
Reported Reproducibility of Serum Proteomic Tests for Ovarian Cancer. Journal of the National
Cancer Institute, 97: 307-309, (with commentary).
[32] Morris JS, Coombes KR, Kooman J, Baggerly KA, and Kobayashi R (2005). Feature
Extraction and Quantification for Mass Spectrometry Data in Biomedical Applications Using
the Mean Spectrum. Bioinformatics, 21(9): 1764-1775.
[33] Coombes KR, Morris JS, Hu J, Edmondson SR, and Baggerly KA (2005). Serum Proteomics
Profiling: A Young Technology Begins to Mature. Nature Biotechnology, 23(3): 291-292.
[34] Hu J, Coombes KR, Morris JS, and Baggerly KA (2005). The Importance of Experimental
Design in Proteomic Mass Spectrometry Experiments: Some Cautionary Tales. Briefings in
Genomics and Proteomics, 3(4), 322-331.
[35] Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, and Kuerer HM (2005). Improved Peak
Detection and Quantification of Mass Spectrometry Data Acquired from Surface-Enhanced
Laser Desorption and Ionization by Denoising Spectra with the Undecimated Discrete Wavelet
Transform. Proteomics, 5: 4107-4117.
[36] Baggerly KA, Coombes KR, and Morris JS (2005). Are the NCI/FDA Ovarian Proteomic Data
Biased? A Reply to Producers and Consumers. Cancer Informatics, 1(1): 9-14.
[37] Coombes KR, Koomen, JM, Baggerly KA, Morris JS, and Kobayashi R (2005). Understanding
the characteristics of mass spectrometry data through the use of simulation. Cancer Informatics,
1(1): 41-52.
[38] Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A, Wallace MJ, Morello FA Jr,
Ahrar K, Murthy R, Lunagomez S, Hicks ME, Vauthey JN (2005). Transhepatic ipsilateral
right portal vein embolization extended to segment IV: improving hypertrophy and resection
outcomes with spherical particles and coils. Journal of Vascular and Interventional Radiology,
2(1): 215-225.
[39] Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust
J, Yao JC, Nivers R, Morris JS, and Pisters PW (2005). Paclitaxel-based chemoradiotherapy
in localized gastric carcinoma: Degree of pathologic response and not clinical parameters
dictated patient outcome. Journal of Clinical Oncology, 23(6), 1237-1244.
[40] Hu, J, Yin G, Morris JS, Zhang L, and Wright FA (2005). Entropy and Survival-based Weights
to Combine Affymetrix Array Types in the Analysis of Differential Expression and Survival.
Methods of Microarray Data Analysis IV, eds. JS Shoemaker and SM Lin, pp. 95-108, New
York: Springer-Verlag.
[41] Morris JS, Yin G, Baggerly KA, Wu C, and Zhang L (2005). Pooling Information Across
Different Studies and Oligonucleotide Microarray Chip Types to Identify Prognostic Genes for

6

JEFFREY S.MORRIS
Lung Cancer. Methods of Microarray Data Analysis IV, eds. JS Shoemaker and SM Lin, pp.
51-66, New York: Springer-Verlag, 2005 (Won best presentation at CAMDA 2003 meetings).
[42] Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A,
Hamilton SR, and Wu TT (2005). Posttherapy pathological stage predicts survival in patients
with esophageal carcinoma receiving preoperative chemoradiation. Cancer, 103(7), 1347-1355.
[43] Beach R, Chan AOO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP,
Hamilton SR, and Rashid A (2005). BRAF mutations in aberrant crypt foci and hyperplastic
polyposis. The American Journal of Pathology, 166(4), 1069-1075.
[44] Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris JS, Liao
Z, Komaki R, and Ajani JA (2005). Value of baseline positron emission tomography for
predicting overall survival in patients with non-metastatic esophageal or gastroesophageal
junction carcinoma. Cancer, 104(8): 1620-1626.
[45] Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R,
Hamilton SR, Lynch P, Levin B, Fischer SM, and Lippman SM (2005). Critical role of 15-
Lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer
Research, 65(24): 11486-92.
[46] Morris JS and Carroll RJ (2006). Wavelet-Based Functional Mixed Models. Journal of the
Royal Statistical Society, Series B, 68(2): 179-199.
[47] Morris JS, Arroyo C, Coull B, Ryan LM, Herrick R, and Gortmaker SL (2006). Using
Wavelet-Based Functional Mixed Models to Characterize Population Heterogeneity in
Accelerometer Profiles: A Case Study. Journal of the American Statistical Association,
101(476): 1352-1364.
[48] Mayo MS, Gajewski BJ, and Morris JS (2006): Some Statistical Issues in Microarray Gene
Expression Data. Radiation Research, 165(6): 745-748.
[49] Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I
(2006). Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of
PPAR-gamma activity. Oncogene, Feb 23;25(8):1225-41.
[50] Baggerly KA, Coombes KR, and Morris JS (2006). An Introduction to High-Throughput
Bioinformatics Data. Bayesian Inference for Gene Expression and Proteomics, KA Do, P
Mueller, and M Vannucci, eds., Cambridge University Press, 1-39.
[51] Guindani M, Do KA, Muller P, and Morris JS (2006). Bayesian Mixture Models for Gene
Expression and Protein Profiles. Bayesian Inference for Gene Expression and Proteomics, KA
Do, P Mueller, and M Vannucci, eds., Cambridge University Press, 238-253.
[52] Morris JS, Baggerly KA, and Coombes KR (2006). Shrinkage Estimation for SAGE Data using
a Mixture Dirichlet Prior. Bayesian Inference for Gene Expression and Proteomics, KA Do, P
Mueller, and M Vannucci, eds., Cambridge University Press, 254-268.
[53] Morris JS, Brown PJ, Baggerly KA, and Coombes KR (2006). Analysis of Mass Spectrometry
Data Using Bayesian Wavelet-Based Functional Mixed Models. Bayesian Inference for Gene
Expression and Proteomics, KA Do, P Mueller, and M Vannucci, eds., Cambridge University
Press, 269-292.

7

JEFFREY S.MORRIS
[54] Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW,
Feig BW, Gunderson LL, and Ajani JA (2006). Surgical pathology stage by The American
Joint Commission On Cancer (AJCC) criteria predicts patient survival after preoperative
chemoradiation for localized gastric carcinoma. Cancer, 107(7): 1475-1482.
[55] Krishnan S, Janjan NA, Skibber JM, Rodrigues-Bigas MA, Wolff RA, Das P, DELclos ME,
Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris JS, Vadhan-Raj S,
Hamilton SR, and Lin EH (2006). Phase II study of capecitabine (Xeloda) and concomitant
boost radiotherapy in patients with locally advanced rectal cancer. Journal of Radiation
Oncology, Biology, and Physics, 66(3): 762-771.
[56] Herrick RC, Morris JS (2006). Wavelet-based functional mixed model analysis: Computational
Considerations. Proceedings, Joint Statistical Meetings, ASA Section on Statistical Computing,
2051-2053.
[57] Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris JS, Ayers
GD, Ross A, Brown T, Rodriguez-Bigas MA, and Janjan N (2006). Retrospective study of
capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the
common mediator in pain, toxicities and survival? Journal of Clinical Oncology, 29(3): 232-9.
[58] Karpievitch YV, Hill EG, Morris JS, Coombes KR, Baggerly KA and Almeida JS (2007).
PrepMs. Bioinformatics 23(2): 264-265.
[59] Song JJ, Lee HJ, Morris JS, and Kang S (2007). Clustering of time-course gene expression data
using functional data analysis. Computational Biology and Chemistry, 31(4), 265-274.
[60] Gutstein HB and Morris JS (2007). Laser capture sampling and analytical issues in proteomics.
Expert Reviews in Proteomics, 4(5), 627-637.
[61] Anandasabapahty S, Jhamb J, Davila M, Wei C, Morris JS, and Bresalier R (2007). Clinical
and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer, 109(4):
558-574.
[62] Cradock AL, Melly SJ, Allen JG, Morris JS, and Gortmaker SL (2007). Characteristics of
school campuses and youth physical activity: Does size matter? American Journal of
Preventative Medicine, 33(2): 106-113.
[63] Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris JS, Pisters PW, Feig B,
Sunder PK, Izzo JG, Ajani JA (2007). Clinical stage after preoperative chemoradiation is a
better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer,
110(5): 989-995.
[64] Coombes, KR, Baggerly KA, and Morris JS (2007). Pre-Processing Mass Spectrometry Data.
Fundamentals of Data Mining in Genomics and Proteomics, W Dubitzky, M Granzow, and D
Berrar, eds. Kluwer, Boston, 79-99.
[65] Thomas MB, Chadha R, Glover K, Wang X, Morris JS, Brown T, Rashid A, Dancey J, and
Abbruzzesse JL (2007). A phase II study of Erlotinib (OSI 774) in patients with unresectable
hepatocellular carcinoma. Cancer, 110(5): 1059-1067.
[66] Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, and Lippman SM (2007). The
transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in
vitro in human colon cancer. FASEB Journal, 21(3): 743-753.

8

JEFFREY S.MORRIS
[67] Chan AOO, Jim MH Lam KF, Morris JS, Siu DCW, Tong T, Ng FH, Wong SY,
Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S,
Szeto ML, Wong BCY, and Lam SK (2007). Association of colorectal cancer and
ademonas in patients with newly diagnosed coronary artery disease: a cross
sectional study. Journal of the American Medical Association, 98(12): 1412-1419.
[68] Morris JS, Clark BN and Gutstein HB (2008). Pinnacle: A Fast, Automatic Method for
Detecting and Quantifying Protein Spots in 2-Dimensional Gel Electrophoresis Data.
Bioinformatics, 24, 529-536.
[69] Gutstein HB, Morris JS, Annangudi SP, and Sweedler JV (2008). Microproteomics: Analysis
of protein diversity in small samples. Mass Spectrometry Reviews, 27, 316-330.
[70] Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I (2008). 15-Lipxygenase-1
transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.
FASEB Journal, 22(6): 1981-92.
[71] Suehiro Y, Wong CW, Chireac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan
TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris JS, Issa JP,
Yuen ST, Leung SY and Hamilton SR (2008). Epigenetic-genetic interactions in the
APC/WNT, RAS/RAF and P53 pathways colorectal carcinoma. Clinical Cancer Research,
14(9): 2560-2569.
[72] Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I
(2008). Therapeutic molecular targeting of 15-Lipoxygenase-1 in colon cancer. Molecular
Therapy, 16(5): 886-892.
[73] Morris JS (2008). Statistical Issues in Proteomic Research. Bulletin of the International
Society for Bayesian Analysis, 14(4), 9-13.
[74] Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy
ML, Abbruzzese JL, Li D (2008). Interaction of the cytochrome P4501A2, SULT1A1 and NAT
gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of
pancreatic cancer. Carcinogenesis, 29(6):1184-91.
[75] Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris JS, Abbruzzesse JL, Ajani JA,
and Wolff RA (2008). Chemotherapy with 5-fluorouracil and a platinum compound improves
outcomes in metastatic small bowel adenocarcinoma. Cancer, 2008 Oct 15; 113(8): 2038-45.
[76] Morris JS (2008). Comment on “Sure independence screening for ultra-high dimensional
feature space,” by Jianqing Fan and Jinchi Lv, Journal of the Royal Statistical Society Series B,
70:5, 900-901.
[77] Morris JS, Brown PJ, Herrick RC, Baggerly KA, and Coombes KR (2008). Bayesian Analysis
of Mass Spectrometry Data using Wavelet Based Functional Mixed Models. Biometrics, 12,
479-489.
[78] Zuo X, Morris JS, and Shureiqi I (2009). Chromatin modification requirements for 15-
lipoxygenase-1 transcriptional reactivation in colon cancer cells. J Biol Chem., 283(46): 31341-
7.

9

JEFFREY S.MORRIS
[79] Li D, Suzuki H, Liu B, Morris JS, Liu J, Okazaki T, Li Y, Chang P, and Abbruzzese JL (2009).
DNA repair gene polymorphisms and risk of pancreatic cancer. Clinical Cancer Research, 15:
740-746.
[80] Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M,
and Abbruzzese J (2009). Phase II trial of the combination of Bevacizumab and Erlotinib in
patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology, 27(6):
843-850.
[81] Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL,
and Wolff RA (2009). Phase II study of Capecitabine and Oxaliplatin for advanced
adenocarcinoma of the small bowel and ampulla of vater. Journal of Clinical Oncology, 2009
Jan 21 (Epub ahead of print).
[82] Kamat P, Wen S, Morris JS, and Anandasabapathy S (2009). Exploring the association
between elevated body mass index and Barrett’s esophagus: a systematic review and meta-
analysis. Annals of Thoracic Surgery, 87(2): 655-662.
[83] Morris JS, Wu C, Coombes KR, Baggerly KA, Wang J, and Zhang L (2009). Alternative
Probeset Definitions for Combining Microarray Data Across Studies Using Different Versions
of Affymetrix Oligonucleotide Arrays. Meta-Analysis and Combining Information in Genetics
and Genomics, eds. Rudy Guerra and Darlene Goldstein, Chapman-Hall, in press.
[84] Morris JS, Baggerly KA, Gutstein HB, and Coombes KR (2009). Statistical contributions to
proteomic research. The Urine Proteome, Humana, in press.
[85] Zuo X, Morris JS, Broaddus R, and Shureiqi I (2009). 15-LOX-1 transcription suppression
through the NuRD complex in colon cancer cells. Oncogene 28(12): 1496-1505.
[86] Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters
PW, Evans DB (2009). Influence of obesity on cancer-related outcomes after pancreatectomy to
treat pancreatic adenocarcinoma. Arch Surg. 144(3): 216-221.
[87] Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, and Shureiqi I (2009).
Targeted PPAR-δ genetic disruption profoundly inhibits colon tumorigenesis. Journal of the
National Cancer Institute, 101(10): 762-767.
[88] Li D, Morris JS, Li J, Hassan MH, Day RS, Bondy ML, and Abbruzzese JL (2009). Body mass
index and risk, age of onset, and survival in pancreatic cancer patients. Journal of the
American Medical Association, 301(24), 2553-2562.
[89] Morris JS (2009). Review of “Wavelet Methods in Statistics with R” by GP Nason.
Biometrics, in press.
[90] Cradock AL, Melly SJ, Allen JG, Morris JS, Gortmaker SL (2009). Youth destinations
associated with objective measures of physical activity in adolescents. Journal of Adolescent
Health, 45(3): S91-98.
[91] Morris JS, Clark BN, Wei W, and Gutstein HB (2010): Evaluating the performance of new
approaches to spot quantification and differential expression in 2-dimensional gel
electrophoresis studies. Journal of Proteome Research, 9(1): 595-604.

10

JEFFREY S.MORRIS
[92] Morris JS (2010): Member’s Discoveries: Fatal flaws in cancer research. IMS Bulletin, 39(1),
5.
[93] Dowsey AW, Morris JS, Gutstein HG, Yang GZ (2010): Informatics and Statistics for
Analyzing 2-D Gel Electrophoresis Images. Methods in Molecular Biology, 604: 239-255.
[94] Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover K, Adinin R, Overman M, Valero V,
Wen S, Lieu C, Yan S, Tran H, Ellis LM, Abbruzzesse JL, and Heymachl JV (2010). Phase II
Trial of Infusional 5-Fluorouracil, Irinotecan and Bevacizumab (FOLFIRI+B) for Metastatic
Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated with
Therapeutic Resistance. Journal of Clinical Oncology, to appear.
[95] Malloy EJ, Morris JS, Adar SD, Suh HH, Gold DR, and Coull BA (2010): Wavelet-based
functional linear mixed models: an application to measurement error corrected distributed lag
models. Biostatistics, to appear.
Submitted Papers:
[1] Baladandayuthapani V, Ji Y, Talluri R, Nieto-Barajas LE, and Morris JS: Bayesian Random
Segmentation Models to Identified Shared Copy Number Aberrations for Array CGH Data.
(Under revision for JASA)
[2] Morris JS, Baladandauthapani V, Herrick RC, Sanna PP, and Gutstein HG: Automated analysis
of quantitative image data using isomorphic functional mixed models, with application to
proteomic data. (Submitted to Annals of Applied Statistics)
[3] Zhu H, Brown PJ, and Morris JS: Robust Functional Mixed Models. (Submitted to JRSS-B)
[4] Kaseb A*, Xiao L, El-Deeb A, Kumar V, Lin E, Abdalla EK, Vauthey JN, Curley SA, Ellis L,
Abbruzzese JL, Hassan MM, and Morris JS*: Incorporating plasma VEGF level into a V-CLIP
scoring system improves stratification of patients with hepatocellular carcinoma. (Submitted to
Clinical Cancer Research)
[5] Hrafnkelsson B, Morris JS, Baladandayuthapani V: Spatial Modeling of Annual Minimum and
Maximum Temperature in Iceland.
[6] Dowsey AW, English JA, Lisacek F, Morris JS, Yang GZ, and Dunn MJ: Image analysis tools
and emerging algorithms for expression proteomics (Under revision for Proteomics)
[7] Sabath N, Morris JS, and Graur D: Detection of functional overlapping genes using population-
level data. (Submitted to PloS Computational Biology)
[8] Diao L, Coombes KR, Clarke CH, Baggerly KA, Morris JS, Hamilton SR, Roth J, Mao L,
Czerniak B, and Bast, Jr. RC: Reproducibility of SELDI spectra across time and laboratories.
[9] Shureiqi I, Chen D, Day RS, Hochman FL, Ross W, Cole RA, Moy O, Morris JS, Xiao L,
Newman R, Yang P, and Lippman SM: Lipoxygenase Metabolism Profiling in the Multi-steps
of Colonic Tumorigenesis. (Under revision for Cancer Prevention Research)
[10] Fogelman D, Jafari M, Varadhachary GR, Xiong H, Chang D, Bullock S, Ozer H, Bennett B,
Cunningham P, Lin E, Morris JS, Abbuzzesse JL, and Wolff RA: Phase II Trial of
Bevacizumab plus Gemcitabine and Oxaliplatin as First-Line Therapy for Metastatic or Locally
Advanced Pancreatic Cancer.

11

JEFFREY S.MORRIS
[11] Shureiqi I, Chen D, Day RS, Hochman FL, Ross W, Cole RA, Moy O, Morris JS, Xiao L,
Newman R, Yang P, and Lippman SM: Ubiquitous Loss of 15-Lipoxygenase-1 Expression and
Terminal Cell Differentiation Evasion in Cancer Cells. (Submitted to Cancer Research).

POSTDOCTORAL RESEARCHERS
[1] Hongxiao Zhu, 2009-present

STUDENTS

[1] Jijun Xu, PhD, GSBS, Supervisory Committee, 2004-2006.

[2] Katherine Barker, PhD, GSBS, Supervisory Committee, 2004-2009.

[3] Michael Lecocke, PhD, Rice, Supervisory Committee, 2003-2005.

[4] Alena Ixmoscane Scott, PhD, Rice, Supervisory Committee, 2004-2006.

[5] Julie Beaver, MS, UT School of Public Health, Predoctoral Fellow, 2004.

[6] Cameron Jeter, PhD, GSBS, Supervisory Committee, 2008-present.

[7] Jens Johansson, PhD, University of Copenhagen, Mentor, 2009.

[8] Changlu Liu, PhD, GSBS, Tutorial Mentor, 2009.

[9] Pan Tong, PhD, GSBS, Supervisory Committee, 2009-present.

[10] Selina Vattithil, PhD, GSBS, Advisory Committee, 2010-present.

[11] Chunyan Cai, PhD, GSBS, Chair, Examination Committee, 2010-present.

INVITED PRESENTATIONS

I have presented 86 invited lectures, including the following:
Mayo
Clinic
2000
University
of
Michigan 2000
University
of
Florida
2000
University
of
New
Mexico
2000
University
of
Chicago
2000
Duke
University
2000
Fred
Hutchinson
Cancer
Research
Center
2000
North
Carolina
State
University
2000


The University of Texas MD Anderson Cancer Center


2000
Rice
University 2001
University
College
of
London 2001

University
of
Kent,
Canterbury
UK
2001
Southern
Methodist
University 2001
Mississippi
State
University
2001

Texas
A&M
University 2001

12

JEFFREY S.MORRIS
Yale
University 2002
Harvard
University
2002
University
of
North
Carolina
2002
Texas
A&M
University 2002

St.
Cloud
State
University
2002
ENAR
Spring
Meeting 2002


7th Valencia International Meeting on Bayesian Statistics

2002
ENAR
Spring
Meeting 2003
WNAR
Summer
Meeting
2003
Joint
Statistical
Meetings
2003
Critical Assessment of Microarray Data Analysis


2003
Texas
A&M
University 2003


University of Texas, School of Public Health



2003
ENAR
Spring
Meeting 2004
ISBA
World
Meetings 2004
International
Biometrics
Conference
2004
Advancing
Practice,
Instruction, and Innovation through Informatics
2004
Rice
University 2004
Texas
A&M
University 2004
Los
Alamos
National
Laboratories
2004
University
of
Pennsylvania
2004
Harvard
University

2004
ENAR
Spring
Meeting 2005
EMR
Meeting
of
the
IBS
2005
ICSA
Applied
Statistics
Symposium
2005
WNAR
Summer
Meeting
2005
Joint
Statistical
Meetings
2005
Johns
Hopkins
University
2005
University
of
Texas,
Dallas
2005
ICSA
Applied
Statistics
Symposium
2006
International
Workshop
on
Applied
Probability
2006
Clinical
Proteomics
in
Oncology
Conference 2006
Joint
Statistical
Meetings
2006
University
of
Washington
2006
University
of
Minnesota
2006
International
Indian
Statistical
Association
Meeting
2007
ENAR
Spring
Meeting 2007
Current
and
Future
Trends
in
Nonparametrics 2007


Institute for Pure and Applied Mathematics Workshop


2007
McGill
University
2007
Columbia
University
2007
Brown
University
2007


National Institute of Allergy and Infections Diseases


2007
University
of
North
Carolina
2007
North
Carolina
State
University
2007
Georgetown
University 2007
University
of
Michigan 2007
St.
Mary’s
University
2007

13

JEFFREY S.MORRIS
ENAR
Spring
Meeting 2008


Statistical Theory and Methods for Complex, High-Dimensional Data
2008
SRCOS
Summer
research
Conference 2008
WNAR
Summer
Meeting
2008
International
Biometrics
Conference
2008
ISBA
World
Meetings 2008
Prairie
View
A&M
University 2008
Imperial
College
London
2008
Fred Hutchinson Cancer Research Center




2008
Texas
A&M
University 2008
Rice
University 2008
University
of
Rochester 2008
WNAR
Summer
Meeting
2009
Joint
Statistical
Meetings
2009
International
Statistical
Institute
Meetings
2009
University
of
South
Carolina
2009
Kansas
University
Medical
Center
2009
ENAR
Spring
Meetings
2010
SRCOS
Meetings
2010
Joint
Biostatistics
Symposium,
China 2010
Joint
Statistical
Meetings
2010

PROFESSIONAL SERVICE

Editorial Responsibilities
 Associate Editor, Biometrics (2006-2011).
 Associate Editor, Journal of the Royal Statistical Society, Series B, (2006-2010).
 Associate Editor, Annals of Applied Statistics (IMS), (2006-2014).

Journal Reviewer:
I have reviewed numerous journal articles, including articles in:
Journal of the American Statistical Association, Journal of the Royal Statistical Society
(Series B), Biometrics, Annals of Statistics, Annals of Applied Statistics, Statistical Science,
Biostatistics, Technometrics, Journal of Computational and Graphical Statistics, Journal of
the Royal Statistical Society (Series C), Journal of Statistical Planning and Inference,
Statistics in Medicine, Journal of Agricultural, Biological, and Environmental Statistics,
Bioinformatics, Proteomics, Proteins, BMC Bioinformatics, Current Bioinformatics,
IEEE/ACM Transactions on Computational Biology and Bioinformatics, Genomic Signal
Processing, Journal of the National Cancer Institute, Cancer Informatics, Communications
in Statistics, Journal of VLSI Signal Processing, Clinical Cancer Research,
Neuropharmacology, Nucleic Acids Research, Molecular and Cellular Proteomics, Journal
of Cellular and Molecular Medicine, Chemometrics and Intelligent Laboratory Systems,
Journal of Microscopy, Physiological Genomics, Drug Information Journal, International
Journal of Imaging Systems and Technology.

Conference Organizer:
 Invited Session Organizer, ENAR 2002

14

JEFFREY S.MORRIS
 Invited Session Organizer, WNAR 2003
 Session Organizer, Conference of Texas Statisticians, 2003.
 Invited Session Organizer, ENAR 2005.
 Invited Session Organizer, WNAR 2005.
 Topic Contributed Session Organizer, IBC 2006.
 Program Chair, Biometrics Section of the American Statistical Association, ENAR 2006.
 Invited Session Organizer, ENAR 2006.
 Invited Session Organizer, JSM 2006.
 Program Committee Member, ENAR 2007.
 Invited Session Organizer, ENAR 2007.
 Member, Organizing Committee, “Statistical Methods for Complex Data” 2009.
 Invited Session Organizer, JSM 2009.
 Program Co-chair, ENAR 2010.
 IMS Invited Session Organizer, ENAR 2010.
 Organizing Committee, “Bayesian Biostatistics” 2010.
 Organizing Committee, SRCOS 2010.

Other Professional Service:
 Council of Sections Representative, ASA Section on Nonparametric Statistics, 2010
 NIH Study Section Member, R13 2009-2010, SBIR 2010
 Susan G. Komen for the Cure’s Targeted Therapies-5 Study Section, 2009.
 Member of Regional Advisory Board, ENAR, 2004-2006.
 Student Paper Review Committee, WNAR 2004.
 Student Paper Review Committee, ENAR 2005-2007.


Institutional Service (MD Anderson):
 Study Section Member, Internal Research Grants, 2005-2008.
 Study Section Member, ACS Institutional Research Grants, 2008-2009.
 Member, Faculty Compensation Committee, MD Anderson Cancer Center, 2006-2009.
 Chair, Faculty Compensation Committee, MD Anderson Cancer Center, 2007-2009.
 Faculty Senate Member, MD Anderson Cancer Center, 2006-2009.
 Faculty Appeals Committee Member, MD Anderson Cancer Center, 2009-2012.
 Clinical Research Council 3, MD Anderson Cancer Center, 2009-2010.


15